Every Form 4 that SCYNEXIS, Inc. (SCYX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SCYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCYX filings page.
SCYNEXIS INC (SCYX) reported that director Steven Keith Burke received new equity awards on September 18, 2026. He was granted 5,750 restricted stock units, each convertible into one share of common stock as they vest, and 5,750 stock options to buy common shares at an exercise price of $4.46 per share, expiring on September 18, 2036. One third of the RSUs will vest each year on the grant-date anniversary starting September 18, 2027, and the options vest one third on the first anniversary of the grant date, with the remaining two thirds vesting in equal monthly installments over the following 24 months, in each case contingent on his continued service. Following these awards he holds 5,750 common shares directly, plus 5,750 stock options, and no Rule 10b5-1 trading plan is reported.
SCYNEXIS INC (SCYX) reported that its Chief Financial Officer, Sanjay Subramanian, received a grant of stock options on September 9, 2026 to purchase 100,000 shares of common stock at an exercise price of $4.91 per share. These options expire on September 8, 2036 and vest 25% after one year, with the remainder vesting in equal monthly installments over the following 36 months, contingent on continued service.
SCYNEXIS INC director Brian Philippe Tinmouth received new equity awards. On June 26, 2026, he was granted 2,875 shares of Common Stock as a restricted stock unit award, with all shares vesting on the first anniversary of the grant if he continues serving as a non-employee director.
He was also granted a stock option for 2,875 shares of Common Stock at an exercise price of $3.85 per share, expiring on June 25, 2036, which likewise vests in full after one year of continued service. Following the grant, he directly holds 12,125 shares of Common Stock. The share amounts reflect a 1-for-8 reverse stock split effective on May 29, 2026.
Macdonald Guy reported acquisition or exercise transactions in this Form 4 filing.
SCYNEXIS director Guy Macdonald received equity compensation on June 26, 2026, consisting of 2,875 restricted stock units and a stock option for 2,875 shares of common stock at $3.85 per share. Both awards vest in full on the first anniversary of grant if he continues serving as a non-employee director. Following the grant, he directly holds 12,625 common shares. All share amounts reflect SCYNEXIS’s 1-for-8 reverse stock split effective May 29, 2026.
SCYNEXIS Inc director Armando Anido reported receiving equity-based compensation. He was granted 2,875 shares of Common Stock as restricted stock units and 2,875 stock options, both at no cost to him. The options have an exercise price of $3.85 per share and expire on June 25, 2036.
All 2,875 restricted stock units and the 2,875 options vest 100% on the first anniversary of the grant date, provided he continues serving as a non-employee director on that vesting date. After these grants, Anido directly holds 11,750 Common shares and 2,875 options. The share amounts reflect a 1-for-8 reverse stock split effective May 29, 2026.
SCYNEXIS director David C. Hastings received new equity awards as part of his compensation. He was granted 2,875 shares of common stock and a stock option for 2,875 shares at an exercise price of $3.85 per share. Both the restricted stock units and the option vest 100% on the first anniversary of the June 26, 2026 grant date, as long as he continues serving as a non-employee director. After the stock grant, he directly holds 11,522 common shares, and the new option expires on June 25, 2036. All amounts reflect a 1-for-8 reverse stock split effective May 29, 2026.
HANHAM ANN reported acquisition or exercise transactions in this Form 4 filing.
SCYNEXIS director Ann Hanham received new equity awards in the form of common stock and stock options. She was granted 2,875 shares of common stock at no cost and 2,875 stock options with a strike price of $3.85 per share. All 2,875 restricted stock units and all 2,875 options vest in full on the first anniversary of the grant date if she continues serving as a non-employee director. After the stock grant, she directly holds 11,577 shares of common stock.
SCYNEXIS INC Chief Executive Officer David Angulo Gonzalez purchased additional equity through a private placement. On March 30, 2026, he agreed to buy 108,695 shares of common stock and accompanying warrants to purchase up to 108,695 shares, which closed on April 1, 2026, at a combined purchase price of $0.92 per share and warrant unit. The new Common Warrants will become exercisable once stockholders approve an increase in authorized common shares and will expire on the earlier of five years from issuance or 30 days after SCYNEXIS releases Week 48 topline data from its Phase 2 proof-of-concept clinical study of SCY-770 in autosomal dominant polycystic kidney disease. Following these transactions, he directly owns 1,357,126 shares of common stock, including 4,000 acquired under the 2014 Employee Stock Purchase Plan.
SCYNEXIS Inc. reported an equity award to its Chief Financial Officer. On 01/29/2026, CFO Macleod Ivor received 129,833 shares of common stock at a price of $0, reported as an acquisition.
These shares represent restricted stock units that vest in three equal annual installments starting February 28, 2026. Following this grant, the officer beneficially owns 398,529 shares directly.
SCYNEXIS Inc. granted equity compensation to its Chief Legal Officer, Scott Sukenick. On January 29, 2026, he received 129,833 shares of common stock at a price of $0 per share in the form of restricted stock units. These units vest one third per year over three years starting February 28, 2026, providing time-based retention incentives. Following this grant, he beneficially owns 574,539 shares of SCYNEXIS common stock in direct ownership.
SCYNEXIS Inc. reported an equity award to its CEO, David Angulo Gonzalez. On January 29, 2026, he received 391,333 shares of common stock as a stock-based grant priced at $0 per share, structured as restricted stock units.
After this award, he beneficially owned 1,244,431 shares of SCYNEXIS common stock in total. The restricted stock units vest in three equal annual installments, with vesting measured from February 28, 2026, which ties the award to multi‑year service and performance with the company.
SCYNEXIS (SCYX) reported an insider transaction on a Form 4. On 10/17/2025, a company Chief Executive Officer and Director acquired 32,500 shares of common stock at $0.76 per share. Following this trade, the insider’s beneficial ownership stands at 853,098 shares, held directly.
The filing notes this total includes 4,000 shares acquired under the 2014 Employee Stock Purchase Plan on 09/05/2025.